1. Home
  2. LYRA vs PRPH Comparison

LYRA vs PRPH Comparison

Compare LYRA & PRPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LYRA
  • PRPH
  • Stock Information
  • Founded
  • LYRA 2005
  • PRPH 1989
  • Country
  • LYRA United States
  • PRPH United States
  • Employees
  • LYRA N/A
  • PRPH N/A
  • Industry
  • LYRA Medical/Dental Instruments
  • PRPH Biotechnology: Pharmaceutical Preparations
  • Sector
  • LYRA Health Care
  • PRPH Health Care
  • Exchange
  • LYRA Nasdaq
  • PRPH Nasdaq
  • Market Cap
  • LYRA 18.0M
  • PRPH 14.7M
  • IPO Year
  • LYRA 2020
  • PRPH 1997
  • Fundamental
  • Price
  • LYRA $0.17
  • PRPH $0.73
  • Analyst Decision
  • LYRA Buy
  • PRPH Strong Buy
  • Analyst Count
  • LYRA 5
  • PRPH 1
  • Target Price
  • LYRA $4.50
  • PRPH $11.00
  • AVG Volume (30 Days)
  • LYRA 2.2M
  • PRPH 254.9K
  • Earning Date
  • LYRA 11-12-2024
  • PRPH 11-13-2024
  • Dividend Yield
  • LYRA N/A
  • PRPH N/A
  • EPS Growth
  • LYRA N/A
  • PRPH N/A
  • EPS
  • LYRA N/A
  • PRPH N/A
  • Revenue
  • LYRA $1,471,000.00
  • PRPH $12,753,000.00
  • Revenue This Year
  • LYRA $13.99
  • PRPH $36.93
  • Revenue Next Year
  • LYRA N/A
  • PRPH $132.05
  • P/E Ratio
  • LYRA N/A
  • PRPH N/A
  • Revenue Growth
  • LYRA 3.37
  • PRPH N/A
  • 52 Week Low
  • LYRA $0.17
  • PRPH $0.66
  • 52 Week High
  • LYRA $6.79
  • PRPH $7.48
  • Technical
  • Relative Strength Index (RSI)
  • LYRA 30.70
  • PRPH 16.18
  • Support Level
  • LYRA $0.26
  • PRPH $0.66
  • Resistance Level
  • LYRA $0.28
  • PRPH $0.83
  • Average True Range (ATR)
  • LYRA 0.02
  • PRPH 0.16
  • MACD
  • LYRA -0.01
  • PRPH -0.14
  • Stochastic Oscillator
  • LYRA 1.69
  • PRPH 4.62

About LYRA Lyra Therapeutics Inc.

Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver up to six months of continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.

About PRPH ProPhase Labs Inc. (DE)

ProPhase Labs Inc is a diversified company that offers a range of services including diagnostic testing, genomics testing and contract manufacturing. Its operating segments include Diagnostic services and Consumer products. The Diagnostic segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third-party payers and government organizations. The Consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and also provide personal genomics products and services.

Share on Social Networks: